Document is current

Any future updates will be listed below

Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week phase II study

Crossref DOI link: https://doi.org/10.1136/lupus-2025-001689

Published Online: 2025-10-29

Published Print: 2025-07

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark